Concepedia

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts

Denis M. Schewe, Ameera Alsadeq, Cornelia Sattler, Lennart Lenk, Fotini Vogiatzi, Gunnar Cario, Simon Vieth, Thomas Valerius, Fabian Meyersieck, Julia Alten,

Blood · 2017 · 37 citations · 44 references

DOIFull text

Open access

Concepts

Abstract

Key Points Fc-engineered CD19 antibody cures MRD in ∼50% of mice xenografted with ALL cells and is highly synergistic in combination with chemotherapy. Macrophages are important effector cells for this antibody in vitro and in vivo.

References

44

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Paul Carter, Leonard G. Presta, C Gorman et al. · Proceedings of the National Academy of Sciences · 1992 · 1.9K citations

, , +16

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Guillaume Cartron, Laurent Dacheux, Gilles Salles et al. · Blood · 2002 · 1.9K citations · Full text

, , +16

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Wen‐Kai Weng, Ronald Levy · Journal of Clinical Oncology · 2003 · 1.3K citations

, , +13

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp, Nicola Gökbuget, Anthony S. Stein et al. · The Lancet Oncology · 2014 · 1.3K citations

, , +13

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 913 citations · Full text

, , +16